Latest News in the pharma Industry

Research & Development

Bavarian Nordic announces collaboration to evaluate CV301 and Tecentriq in bladder cancer

Bavarian Nordic announces collaboration to evaluate CV301 and Tecentriq in bladder cancer

12 Mar 2017

Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.

Read more 
Horizon Discovery enters into R&D and licensing partnership for bioproduction cell line optimisation

Horizon Discovery enters into R&D and licensing partnership for bioproduction cell line optimisation

9 Mar 2017

Partnership formed to evaluate the impact of Amplycell’s novel cell fitness technology on expression capacity of Horizon’s bioproduction cell line.

Read more 
FDA accepts sNDA for Vraylar

FDA accepts sNDA for Vraylar

8 Mar 2017

Application seeks to expand Vraylar label to include Phase III clinical data for the maintenance treatment of schizophrenia.

Read more 
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

7 Mar 2017

Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin.

Read more 
Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis

Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis

6 Mar 2017

Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.

Read more 
GSK study shows Nucala significantly improves quality of life and lung function in severe asthma patients

GSK study shows Nucala significantly improves quality of life and lung function in severe asthma patients

6 Mar 2017

Provides hope for patients with severe asthma, who currently have very limited treatment options.

Read more 
Sandoz proposed biosimilar adalimumab demonstrates equivalent efficacy as Humira

Sandoz proposed biosimilar adalimumab demonstrates equivalent efficacy as Humira

6 Mar 2017

Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

Read more 
Sanofi Pasteur and MedImmune collaborate on monoclonal antibody to prevent illnesses associated with RSV

Sanofi Pasteur and MedImmune collaborate on monoclonal antibody to prevent illnesses associated with RSV

4 Mar 2017

MEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.

Read more 
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild-type mCRC

NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild-type mCRC

2 Mar 2017

More patients now able to receive a standard-of-care treatment with Erbitux plus Folfiri or Folfox.

Read more 
Astellas and Affinivax announce worldwide partnership for MAPS vaccine targeting pneumococcal disease

Astellas and Affinivax announce worldwide partnership for MAPS vaccine targeting pneumococcal disease

2 Mar 2017

Affinivax’s MAPS vaccine technology overcomes the limitations of current conjugate vaccine technology, creating a MAPS pneumococcal vaccine that enables broader protection.

Read more 
FDA accepts BLA for avelumab for the treatment of metastatic urothelial carcinoma for Priority Review

FDA accepts BLA for avelumab for the treatment of metastatic urothelial carcinoma for Priority Review

28 Feb 2017

Second Biologics License Application accepted by the FDA for avelumab.

Read more 
CHMP recommends EU Conditional Marketing Authorisation for Natpar for patients with chronic hypoparathyroidism

CHMP recommends EU Conditional Marketing Authorisation for Natpar for patients with chronic hypoparathyroidism

27 Feb 2017

If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.

Read more